Indivior (INDV) news
Recent news
Barclays cuts target price to $43 from $46 for Indivior Pharmaceuticals, Inc
Barclays has revised its price target for Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) from $46 to $43, while maintaining an overweight rating . The adjustment follows the firm’s continued assessment of the company’s strategic initiatives and financial performance. Indivior has demonstrated strong…
AInvest Wire · Aug 5, 2026Indivior 2Q operating profit $160M vs. $72M y/y
Indivior Pharmaceuticals, Inc. reported a second-quarter operating profit of $160 million for 2026, compared to $72 million in the same period of the previous year, reflecting significant operational improvements and strategic execution . The increase in operating profit was driven by strong…
AInvest Wire · Aug 3, 2026Indivior 2Q net revenue $343M, estimate $306.8M
Indivior PLC (Nasdaq: INDV) reported second-quarter 2025 net revenue of $302 million, exceeding the consensus estimate of $306.8 million . The company’s total net revenue for the quarter reflects a 1% increase compared to $299 million in the same period of 2024. The growth was primarily driven by…
AInvest Wire · Aug 3, 2026Indivior, Citi enter letter for $650M term loan facility
AInvest Wire · Aug 3, 2026Indivior Pharmaceuticals Inc: Supernus must pay co termination fee of $101 mln if the merger agreement is terminated under certain circumstances
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.